Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Uncovering Similarities Between Prostate Cancer Genomes
Disease Discoveries

Uncovering Similarities Between Prostate Cancer Genomes

By Melissa RohmanAug 19, 2020
Share
Facebook Twitter Email
Zachary Chalmers, a fifth-year student in the Medical Scientist Training Program, was co-lead author of the study published in Clinical Cancer Research.

Genomic alterations in prostate cancer used as therapeutic targets were found to be similar between African American and European American men, suggesting that existing precision medicine approaches could equally benefit both populations if applied equitably, according to findings published in the journal Clinical Cancer Research.

African American men have the highest mortality rate from prostate cancer compared with men of other racial backgrounds. Despite persistent disparities, the genomic characterization of prostate cancer tumors in African American men has remained poorly understood due to the lack of significant numbers of African American men included in past genomic studies.

“Patients of African ancestry are underrepresented in clinical trials and medical research in general, so this study was a meta-analysis effort to determine if any underlying biological differences are driving disease and, ultimately, to better understand why African American men with prostate cancer have worse outcomes,” said Zachary Chalmers, a fifth-year student in the Medical Scientist Training Program (MSTP) in the Abdulkadir laboratory and co-lead author of the study

For the current study, the investigators compared the frequencies of somatic alterations in prostate cancer from four publicly available datasets containing 250 African American men and 611 European American men, as well as targeted sequencing data from a commercial dataset for 436 African American men and 3,018 European men.

The investigators found that while there were notable differences in African American men, the frequencies of genomic alterations in current therapeutic targets for prostate cancer were actually similar between the two groups. These included tumor mutation burden (the measurement of the number of mutations within tumor cells), MSI (microsatellite instability) status — an indication of when genes that repair DNA don’t work correctly — and alterations in select DNA repair genes, as well as in CDK12 and AR.

The findings suggest that current precision medicine approaches could benefit both groups equally, but only if applied equitably. Furthermore, the structural social and economic determinants that drive health disparities must also be considered, according to Chalmers.

“There were differences in a couple of genes, but none of them were clinically actionable or had drug targets, so we can robustly say with a lot of data that these patients can be clinically managed similarly,” Chalmers said.

Sarki Abdulkadir, MD, PhD, the John T. Grayhack, MD, Professor of Urological Research and vice chair for Research in the Department of Urology, was a co-author of the study.

This work was funded by the U.S. Department of Defense grants W81XWH-14-1-0514 and W81XWH-17-PCRP-HD, the National Cancer Institute grants P20 CA233255-01 and U19 CA214253, and the Prostate Cancer Foundation.

Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Surmeier Recognized with Annemarie Opprecht Parkinson Award

Oct 2, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Comments are closed.

Latest News

Surmeier Recognized with Annemarie Opprecht Parkinson Award

Oct 2, 2023

Medical Education Day Celebrates Mentorship and Equity

Sep 29, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230927_MedEdDay_Sargent_6
20230927_MedEdDay_Sargent_3
20230927_MedEdDay_Sargent_1
20230927_MedEdDay_Posters_Patel_2
20230927_MedEdDay_Posters_Patel_1
20230927_MedEdDay_Posters_Panko_1
20230927_MedEdDay_Posters_4
20230927_MedEdDay_Posters_3
20230927_MedEdDay_Posters_2
20230927_MedEdDay_Posters_1
20230927_MedEdDay_Awards_6
20230927_MedEdDay_Awards_5

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.